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A B S T R A C T
The aim of this study is to report short-term effect of the treatment of »wet« ARMD (age-related macular degeneration)
with intravitreal bevacizumab (Avastin). Prospective study included 36 patients (36 eyes) with »wet« form of ARMD. All
patients were over 60 year old (22 female, 14 male). Changes of macula included minimally classic CNV (choroidal
neovascularisation) (24), occult subfoveal CNV (10) and first stage of cicatrial CNV (2). Bevacizumab 1.25 mg was ad-
ministered intravitreally through pars plana using a 27-gauge needle. Patients had no previous eye treatment. Ophthal-
mic exam before and after the treatment included: Snellen VA (visual acuity) and examination including measurement of
IOP (intraocular pressure), FA (fluorescein angiography) and interview with patients. After 4–6 weeks 28 (78%) patients
had significant improvement of VA. Median VA improved from 0.083 to 0.200 (p<0.01). Eight patients (22%) had no sig-
nificant improvement in VA but three of them reported to see more light. FA showed complete resolution of macular
edema in 6 patients (17%), partially resolved in 23 patients (64%) and no change in 7 patients (19%). No systemic side-ef-
fect was found. Short-term results suggest that intravitreally administered bevacizumab is well tolerated treatment for
ARMD with very high number of patients showing improvement in VA.
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Introduction
ARMD affects patients in their retirement years (over
55)1,2. Degenerative changes of macular area results in
damage of central vision. These changes lead to difficulty
in driving and reading. There are two categories of ARMD:
»dry« with drusen deposits and »wet« with CNV. In the
»wet« type bleeding and scaring destroy overlying retina.
For over three decades, standard laser therapy was the
only viable treatment for patients with »wet« form. Only
about 25% of patients with »wet« form were candidates
for this treatment and of those treated about 50% would
experience some form of recurrence of the disease. Al-
most none of patients who were treated with laser expe-
rienced improvement of their vision. In most of the cases
slowing or stabilization of the disease was the best one
could hope for. The newer treatment modalities were
photodynamic therapy, surgical intervention and radia-
tion therapy3. These treatments are in a class of drugs
called »anti-VEGF« therapy. VEGF (Vascular Endothe-
lial Growth Factor) is a protein that is important in form-
ing new blood vessels. Abnormally high concentrations of
VEGF can lead to damage by the growth of new blood
vessels where they would not be, such as under the
macula in the »wet« form of ARMD. This new class of
drugs acts by blocking VEGF and preventing it from
stimulating the growth of these abnormal blood vessels
Pegaptanib (Macugen) represented the first use of anti-
-VEGF factor in the eye4–6. Ranibizumab (Lucentis) was
approved by the US Food and Drug Administration (FDA)
at the end of June 2006 for use in »wet« ARMD. It was
developed for intraocular use and besides preventing of
visual lose it was capable of significantly improving VA of
ARMD patients 6–11. Following the reported benefits of
Lucentis therapy in the summer of 2005, retina special-
ists turned their attention towards bevacizumab, which
is medicine currently FDA approved for the treatment of
metastatic colon cancer. Bevacizumab is molecularly sim-
ilar to ranibizumab and acts in the same way4,6,12.
The advantage of using bevacizumab is lower price
and longer time intervals between administrations4,6,7.
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The purpose of our study was testing safety and efficacy
of bevacizumab in our ARMD patients with CNV.
Patients and Methods
Thirty-six patients (36 eyes) aged >60 years were in-
cluded in this prospective interventional case study. In-
clusion criteria were ARMD with active leakage from
CNV documented by FA, best corrected VA>0.017 and no
previous eye treatment. The off-label use of bevacizumab
was discussed with each patients and written informed
consent was obtained before enrollment. Ophthalmic
evaluation before and after the treatment included: Sne-
llen VA, complete ophthalmic examination including mea-
surement of IOP, FA and interview with patients. The
treatment of bevacizumab was performed in operating
theatre after povidone iodine preparation of eyelids and
conjunctiva. Patients underwent topical anesthesia with
Lidocain gel. Bevacizumab (1.25 mg) was administered
intravitreally through the pars plana using a 27-gauge
needle. After intravitreal treatment retinal artery perfu-
sion, IOP and light appreciations from all four directions
were checked. Patients were followed up every 4–6 weeks
after receiving the first injection and received additional
injection treatment when necessary. The main outcome
measures were changes between baseline and visit after
4–6 weeks in best corrected VA and resolving of macular
edema documented by FA. Changes between baseline
and visit after 4–6 weeks were analyzed using at-test.
Results
Thirty-six eyes of patients (22 female and 14 male),
median age 69.2 (range 62–83) years with CNV second-
ary to ARMD were included. There were 24 eyes with
minimally classic, 10 eyes with occult and two eyes with
first stage of cicatrial CNV documented by FA. Median
duration of follow up was 5.37 (range 4–6 weeks). After
that period 27 (78%) of 36 patients had significant im-
provement of VA. Median vision improved from 0.083 to
0.200 (p<0.01). Eight patients (22%) had no significant
improvement of VA but three patients reported to see
more light. FA showed complete resolved macular edema
in 6 patients (17%), partially resolved edema in 23 pa-
tients (64%) and seven without change (19%). There
were several local side effects. Transitory rise of IOP was
found in four eyes the next day, hyposphagma after the
injection in nine eyes and mild opacities in eight eyes. No
systemic side-effects were found.
Discussion and Conclusion
Before the introduction of anti-VEGF medications
there was no known therapy for ARMD that can actually
improve VA. Several different drugs were recommended
(peptaganib, ranizumab, bevacizumab). Although beva-
cizumab is currently available only as off-label drug,
many published case series and their results encourage
further use in ARMD11,12.
Economic aspect is also very important because this
drug is not expensive compared to other recommended7.
Our short-term results after first injection and 4–6 weeks
of following-up suggest that intravitreally administered
bevacizumab in the dose of 1.25 mg is well tolerated and
associated with reduction in FA leakage and significantly
improvement of VA in most patients. Seventy-eight per-
cent of our patients had significantly improvement of VA.
No systemic side-effects were noticed. Lower cost of
bevacizumab in comparison with other anti VEGF-agents
were also the important factor. We need further evalua-
tion of intravitreal bevacizumab, especially long term re-
sults and frequency of additional intravitreal therapy.
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INTRAVITREALNI BEVACIZUMAB U LIJE^ENJU SENILNE MAKULARNE DEGENERACIJE
S A @ E T A K
Na{a je namjera bila prikazati kratkoro~ne efekte lije~enja vla`ne senilne makularne degeneracije intravitrealno
injiciranim bevacizumabom (Avastinom). Pacijenti su primili injekcije od 1.25 mg bevacizumaba, a kontrolirani su na-
kon razdoblja od 4–6 tjedana. Prospektivna studija uklju~ila je 36 pacijenata, odnosno 36 o~iju sa vla`nim oblikom
senilne makularne degeneracije. Pacijenti nisu prethodno dobivali nikakvu o~nu terapiju. Uklju~eno je 24 pacijenta s
minimalno klasi~nom, 10 sa okultnom i dva sa prvim stadijem o`iljkavanja. Bevacizumab u dozi od 1.25 mg injiciran je
intravitrealno kroz pars plana. Nakon 4–6 tjedana 27 pacijenata (78%) imalo je pobolj{anje vidne o{trine. Od 8 pa-
cijenata kod kojih nije do{lo do pobolj{anja tri su navela da vide vi{e svjetla. Prije i nakon perioda od 4–6 tjedana u~injen
je potpun oftalmolo{ki pregled uklju~uju}i vidnu o{trinu, mjerenje o~nog tlaka, fluoresceinsku angiografiju te razgovor
s pacijentom. Potpuno povla~enje makularnog edema zabilje`ili smo kod 6 pacijenata (17%), djelomi~no kod 23 pa-
cijenta (64%), a nepromijenjeno stanje edema kod 7 pacijenata (19%). Zabilje`ene su bezazlene lokalne nuspojave dok
sustavnih nije bilo. Kratkoro~ni su rezultati ohrabruju}i te pokazuju da pacijenti dobro podnose intravitrealni beva-
cizumab u dozi od 1.25 mg. Nakon ove terapije bitno se popravlja vidna o{trina i smanjuje edem makule kod ve}ine
pacijenata.
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